SCHEMBL3307080

SCHEMBL3307080

O=C(Cn1ccc2ccccc21)Nc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.68
MGLL Q99685 1/20 0.60
NTSR1 P30989 1/20 0.58
LMNA P02545 4/20 0.55
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
NLRP3 Q96P20 1/20 0.53
HSD17B10 Q99714 1/20 0.52
IDO1 P14902 1/20 0.52
GLS O94925 1/20 0.52
USP2 O75604 1/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21466938 0.86 MAPK1 (0.68) KMT2ALMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL22246550 0.86 TDP1 (0.63) KMT2AMGLLLMNAALDH1A1SMN1; SMN2
SCHEMBL4534430 0.83 MGLL (0.64) KMT2AMGLLNTSR1LMNAALDH1A1
SCHEMBL7876613 0.82 KMT2A (0.65) KMT2AMGLLNTSR1LMNAKDM4E
SCHEMBL2593474 0.82 KMT2A (0.65) KMT2AMGLLNTSR1LMNAHSD17B10
SCHEMBL3038469 0.81 MAPT (0.56) KMT2ALMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL6138108 0.81 KMT2A (0.69) KMT2ANTSR1LMNAALDH1A1KDM4E
SCHEMBL29420405 0.81 KMT2A (1.00) KMT2ANTSR1LMNAKDM4EMEN1
SCHEMBL1598786 0.81 KMT2A (1.00) KMT2ANTSR1LMNAKDM4EMEN1
SCHEMBL1608213 0.80 HDAC6 (0.52) KMT2AMGLLLMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099732-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-22 US claimed
EP-2139855-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2010-01-06 EP claimed
WO-2008113747-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-09-25 WO claimed
US-20100099732-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-22 US disclosed
US-20100099732-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-22 US disclosed
EP-2139855-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2010-01-06 EP disclosed
EP-2139855-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2010-01-06 EP disclosed
WO-2008113747-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-09-25 WO disclosed
WO-2008113747-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099732-A1 MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS KCNN2, KCNN1, KCNN3 KMT2A 424/4885MGLL 2160/4885NTSR1 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.